Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58456) - R10 - February 18, 2025

Date Posted: April 25, 2025

This Billing and Coding Article has been revised under contractor numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY).

Effective Date: February 18, 2025

Summary of Changes:

Under Article Text revised subheading Additional Test-specific Indications, Limitations and Instructions (2) added "Non-small cell lung cancer (NSCLC) (Natera)." This revision is due to covered test that has successfully completed a TA and is effective for 2/18/2025.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.

Last Updated Apr 24 , 2025